stockrowProtagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Book value per share
Protagonist Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 9.7×, down 11.8% from 11.0× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 12.8×. Over the past ten years it has ranged from −109× (fiscal 2015) to 13.5× (fiscal 2016); the current reading is higher than 82% of that period. Protagonist Therapeutics, Inc. ranks 65th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 9.7× | (11.84%) |
| FY2024 | 11.0× | 84.93% |
| FY2023 | 5.9× | 34.91% |
| FY2022 | 4.4× | (32.12%) |
| FY2021 | 6.5× | (20.33%) |
| FY2020 | 8.1× | 163.23% |
| FY2019 | 3.1× | (38.62%) |
| FY2018 | 5.0× | (26.20%) |
| FY2017 | 6.8× | (49.37%) |
| FY2016 | 13.5× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 12.8× | 26.74% |
| Mar 2026 | 10.1× | 4.15% |
| Dec 2025 | 9.7× | (4.46%) |
| Sep 2025 | 10.1× | (3.78%) |
| 40 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 48.5× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 21.4× |
| PTGX Protagonist Therapeutics, Inc. | 12.8× |
| SYRE Spyre Therapeutics, Inc. compare | 11.9× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. compare | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement